Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia | NEJM
Whether fixed-duration acalabrutinib–venetoclax (with or without obinutuzumab) would result in better progression-free survival than chemoimmunotherapy in patients with untreated chronic lymphocyti…